PL366327A1 - Agoniści i antagoniści Urotensyny-II - Google Patents

Agoniści i antagoniści Urotensyny-II

Info

Publication number
PL366327A1
PL366327A1 PL01366327A PL36632701A PL366327A1 PL 366327 A1 PL366327 A1 PL 366327A1 PL 01366327 A PL01366327 A PL 01366327A PL 36632701 A PL36632701 A PL 36632701A PL 366327 A1 PL366327 A1 PL 366327A1
Authority
PL
Poland
Prior art keywords
urotensin
agonists
antagonists
features
antagonist
Prior art date
Application number
PL01366327A
Other languages
English (en)
Inventor
Dawid H. Coy
Wojciech J. Rossowski
Original Assignee
The Administrators Of The Tulane Educational Fund
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Administrators Of The Tulane Educational Fund, Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. filed Critical The Administrators Of The Tulane Educational Fund
Publication of PL366327A1 publication Critical patent/PL366327A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL01366327A 2000-10-20 2001-10-19 Agoniści i antagoniści Urotensyny-II PL366327A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24189600P 2000-10-20 2000-10-20

Publications (1)

Publication Number Publication Date
PL366327A1 true PL366327A1 (pl) 2005-01-24

Family

ID=22912605

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01366327A PL366327A1 (pl) 2000-10-20 2001-10-19 Agoniści i antagoniści Urotensyny-II

Country Status (21)

Country Link
US (2) US7241737B2 (pl)
EP (1) EP1355940B1 (pl)
JP (2) JP4081369B2 (pl)
KR (3) KR100820896B1 (pl)
AT (1) ATE374786T1 (pl)
AU (2) AU2002232903B2 (pl)
BR (1) BR0114737A (pl)
CA (1) CA2425804A1 (pl)
CZ (1) CZ299402B6 (pl)
DE (1) DE60130802T2 (pl)
DK (1) DK1355940T3 (pl)
ES (1) ES2291372T3 (pl)
HU (1) HUP0301384A3 (pl)
IL (2) IL155127A0 (pl)
MX (1) MXPA03003297A (pl)
NO (1) NO20031699L (pl)
PL (1) PL366327A1 (pl)
PT (1) PT1355940E (pl)
RU (1) RU2263679C2 (pl)
WO (1) WO2002032932A2 (pl)
ZA (1) ZA200302505B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050014198A1 (en) * 2002-07-11 2005-01-20 Leong Ng Assays and kits for detecting and monitoring heart disease
US7939052B2 (en) * 2005-05-12 2011-05-10 Janssen Pharmaceutica Nv Method of measuring the biological activity of an urotensin II receptor
ES2410207T3 (es) * 2006-10-16 2013-07-01 The Salk Institute For Biological Studies Antagonistas de la somatostatina selectivos para receptor(SSTR2)
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
CA2733117C (en) * 2008-08-08 2016-03-22 Polyphor Ag Template-fixed peptidomimetics
RU2558921C1 (ru) * 2014-06-26 2015-08-10 Анатолий Петрович Бахтинов Способ прекращения течки у самок и остро проявляющейся охоты у самцов млекопитающих животных

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE90108T1 (de) * 1987-10-09 1993-06-15 Takeda Chemical Industries Ltd Vasokonstriktor-peptid.
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US20020107187A1 (en) * 1996-05-22 2002-08-08 Kingston David J. Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
US6262229B1 (en) * 1996-12-04 2001-07-17 Biomeasure Incorporated Somatostatin antagonists
US6159700A (en) * 1997-01-27 2000-12-12 Smithkline Beecham Corporation Method of finding agonist and antagonist to human and rat GPR14
FR2786489B1 (fr) * 1998-11-26 2002-12-27 Inst Nat Sante Rech Med Urotensines ii de mammiferes et leurs appications
JP2003527341A (ja) * 1999-11-29 2003-09-16 スミスクライン・ビーチャム・コーポレイション ウロテンシン−ii類似体
DK1372688T3 (da) * 2001-03-08 2008-08-25 Univ Tulane Somatostatin-antagonister
CN1541102A (zh) * 2001-04-09 2004-10-27 生长激素抑制素激动剂

Also Published As

Publication number Publication date
EP1355940B1 (en) 2007-10-03
MXPA03003297A (es) 2004-05-04
HUP0301384A3 (en) 2010-04-28
JP2005500244A (ja) 2005-01-06
CZ2003900A3 (cs) 2003-12-17
NO20031699L (no) 2003-06-18
ATE374786T1 (de) 2007-10-15
JP4081369B2 (ja) 2008-04-23
RU2263679C2 (ru) 2005-11-10
KR100707408B1 (ko) 2007-04-13
US20070287665A1 (en) 2007-12-13
ZA200302505B (en) 2005-05-30
US20050075480A1 (en) 2005-04-07
AU3290302A (en) 2002-04-29
EP1355940A2 (en) 2003-10-29
DE60130802D1 (de) 2007-11-15
NO20031699D0 (no) 2003-04-11
CA2425804A1 (en) 2002-04-25
WO2002032932A2 (en) 2002-04-25
KR20060090843A (ko) 2006-08-16
WO2002032932A3 (en) 2003-09-04
KR20060090768A (ko) 2006-08-16
HUP0301384A2 (en) 2007-11-28
IL184121A0 (en) 2007-10-31
AU2002232903B2 (en) 2005-06-30
BR0114737A (pt) 2005-06-07
KR100820896B1 (ko) 2008-04-11
DK1355940T3 (da) 2008-01-07
PT1355940E (pt) 2007-11-08
DE60130802T2 (de) 2008-07-03
JP2006342170A (ja) 2006-12-21
KR20030081316A (ko) 2003-10-17
CZ299402B6 (cs) 2008-07-16
US7241737B2 (en) 2007-07-10
HK1059938A1 (en) 2004-07-23
ES2291372T3 (es) 2008-03-01
IL155127A0 (en) 2003-10-31
KR100795427B1 (ko) 2008-01-17

Similar Documents

Publication Publication Date Title
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
DE60108420D1 (en) Morpholinderivate als antagonisten an orexinrezeptoren
ATE172971T1 (de) Heterocyclische neurokinin-antagonisten
EA200200208A1 (ru) Синергитическая композиция
ATE349434T1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
DE69728585D1 (de) Mittel gegen Juckreiz
MY131434A (en) Angiotensin ii antagonists
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
MY137457A (en) Cyclic peptides having melanocortin-4 receptor agonist activity
PT1440059E (pt) Derivados do 3-azabiciclo(3.1.0)hexano como antagonistas de receptores opióides
IL184121A0 (en) Urotensin-ii agonists polypeptide and its use for manufacture of medicaments
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
AU2003239280A1 (en) Combination treatment for depression and anxiety by nk1 and nk3 antagonists
MXPA05007771A (es) Procedimientos de tratamiento del dolor articular o para mejorar el sueno usando un agonista/antagonista de estrogeno.
ATE306272T1 (de) Verwendung von einem aldosteron-rezeptor- antagonisten zur verbesserung der kognitiven funktion
ZA200109836B (en) Therapy for andropause using estrogen agonists/antagonists and testosterone.
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
ATE279923T1 (de) Urotensin-ii rezeptorantagonisten
EP1878743A3 (en) Urotensin-II agonists and antagonists
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
ITFI20030238A1 (it) Peptidi ciclici antagonisti dell'urotensina-ii
MX2007013207A (es) Agente para la profilaxis y tratamiento de la pancreatitis.
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)